Phase 2 N=73 Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
Prostatic Neoplasms
Primary: Number of Participants Who Had a Prostate-specific Antigen (PSA) Response — 52 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=33 Mayo Acute Stroke Trial for Enhancing Recovery
Ischemic Stroke
Primary: Percent of Participants With National Institutes of Health Stroke Scale (NIHSS) Score = 0 or 1 at Day 90 — 69; 33; 0; 45 percentage of participants
Phase 2 N=22 Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer
Carcinoma, Non-small Cell Lung
Primary: Response Rate Defined as the Percentage of Subjects Achieving at Least 50% Tumor Volume Reduction. — 1 Participants — p=<0.01
Phase 2 N=72 Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Response Rate — 26 Percentage of participants
Phase 2 N=75 Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
Lung Cancer
Primary: Pathologic Complete Response Rate — 0 Percentage of participants
Phase 2 N=9 Treatment of Oral Premalignant Lesions With 5-ALA PDT
Leukoplakia · Erythroplakia
Primary: Maximum Tolerated Dose — 8 J/cm2
Phase 2 N=60 Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer
Lung Cancer
Primary: Number of Grade 3/4 Toxicities Patients Experienced on Maintenance Bevacizumab Following Chemoradiation for Limited Stage - Small Cell Lung Cancer (LS-SCLC) — 2; 1; 1; 1…
Phase 2 N=69 Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Clinical Response Rate — 17 Percentage of participants
Phase 2 N=14 Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)
Sensitivity in Esophagus
Primary: Time to Visual Analogue Scale 7 (VAS7) During Thermal Stimulation at 1.5 Hours Post-Dose. — 84.0; 86.9 seconds
Phase 2 N=138 Fish Oil (Omega 3), Immune Function, and Mood
Inflammation
Primary: Serum ln(TNF-a) — 0.66; 0.74; 0.71; 0.11 pg/ml (raw TNF-a) — p=0.03
Phase 2 N=22 Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)
Anxious Major Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HAM-D) Total Score. — 14.249; 16.307 Units on a scale
Phase 2 N=539 Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)
Rhinitis · Seasonal Rhinitis
Primary: Mean Change From Baseline Over the Entire Treatment Period in the Daily Reflective Nasal Congestion Score — -0.460; -0.499; -0.508; -0.461 Units on a Scale — p=0.4912
Phase 2 N=109 APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer
Pancreatic Cancer · Metastatic Pancreatic Cancer
Primary: Progression Free Survival — 3.0; 2.8 Months
Phase 2 N=13 Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma
Neuroblastoma
Primary: Response Rate Associated With Two Cycles of Cisplatin With Protracted Oral Etoposide When Administered as Up-front Window Therapy to Previously Untreated Children With…
Phase 2 N=20 Treatment of Corneal Neovascularization With Topical Pazopanib
Corneal Neovascularization
Primary: Heart Rate — 68.7 Beats per Minutes